NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines

Biochemical and Biophysical Research Communications

Volumn 414, Issue 1, 2011, Pages 123-128

  Erbaykent Tepedelen, Burcu ^a   Özmen, Besra ^a   Varisli, Lokman ^a   Gonen Korkmaz, Ceren ^a   Debelec Butuner, Bilge ^a   Muhammed Syed, Hamid ^a   Yilmazer Cakmak, Ozgur ^b   Korkmaz, Kemal Sami ^a  

^a EGE UNIVERSITY   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

H2AX (S139) foci; DNA damage response; NKX3.1; PATM (S1981); Prostate cancer; Topoisomerase inhibitor CPT 11

Indexed keywords

ANDROGEN; ATM PROTEIN; CHECKPOINT KINASE 2; CYCLIN D1; DNA; HISTONE H2AX; IRINOTECAN; NIBRIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HORMONAL REGULATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TIME;

ANDROGENS; CAMPTOTHECIN; CELL LINE, TUMOR; DNA DAMAGE; HISTONES; HOMEODOMAIN PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; S PHASE; TRANSCRIPTION FACTORS;

EID: 80054070288     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.035     Document Type: Article

References (26)

1. Huggins C. Endocrine-induced regression of cancers. Cancer Res. 1967, 27:1925-1930.
2. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28:251-265.
3. Bruchovsky N., Klotz L.H., Sadar M., Crook J.M., Hoffart D., Godwin L., Warkentin M., Gleave M.E., Goldenberg S.L. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol. Urol. 2000, 4:191-199. discussion 201.
4. Culig Z., Steiner H., Bartsch G., Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 2005, 12:229-244.
5. Van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., van Vroonhoven C.C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 1991, 48:189-193.
6. Korkmaz K.S., Korkmaz C.G., Ragnhildstveit E., Kizildag S., Pretlow T.G., Saatcioglu F. Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens. Gene 2000, 260:25-36.
7. Prescott J.L., Blok L., Tindall D.J. Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 1998, 35:71-80.
8. Zheng S.L., Ju J.H., Chang B.L., Ortner E., Sun J., Isaacs S.D., Sun J., Wiley K.E., Liu W., Zemedkun M., Walsh P.C., Ferretti J., Gruschus J., Isaacs W.B., Gelmann E.P., Xu J. Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. Cancer Res. 2006, 66:69-77.
9. Lei Q., Jiao J., Xin L., Chang C.J., Wang S., Gao J., Gleave M.E., Witte O.N., Liu X., Wu H. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006, 9:367-378.
10. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R., Abate-Shen C., Shen M.M. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999, 13:966-977.
11. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J., Kallioniemi O.P., Gelmann E.P. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000, 60:6111-6115.
12. Guan B., Pungaliya P., Li X., Uquillas C., Mutton L.N., Rubin E.H., Bieberich C.J. Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1. J. Biol. Chem. 2008, 283:4834-4840.
13. Ouyang X., DeWeese T.L., Nelson W.G., Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. 2005, 65:6773-6779.
14. Markowski M.C., Bowen C., Gelmann E.P. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res. 2008, 68:6896-6901.
15. Bowen C., Stuart A., Ju J.H., Tuan J., Blonder J., Conrads T.P., Veenstra T.D., Gelmann E.P. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res. 2007, 67:455-464.
16. Mayeur G.L., Kung W.-J., Martinez A., Izumiya C., Chen D.J., Kung H.-J. Ku Is a Novel Transcriptional Recycling Coactivator of the Androgen Receptor in Prostate Cancer Cells. J. Biol. Chem. 2005, 280:10827-10833.
17. Bowen C., Gelmann E.P. NKX3.1 activates cellular response to DNA damage. Cancer Res. 2010, 70:3089-3097.
18. Korkmaz C.G., Korkmaz K.S., Manola J., Xi Z., Risberg B., Danielsen H., Kung J., Sellers W.R., Loda M., Saatcioglu F. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J. Urol. 2004, 172:1134-1139.
19. Korkmaz K.S., Korkmaz C.G., Pretlow T.G., Saatcioglu F. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and regulation by multiple hormones. DNA Cell Biol. 2001, 20:435-445.
20. Cai Z., Vallis K.A., Reilly R.M. Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software. Int. J. Radiat. Biol. 2009, 85:262-271.
21. Hanasoge S., Ljungman M. H2AX phosphorylation after UV irradiation is triggered by DNA repair intermediates and is mediated by the ATR kinase. Carcinogenesis 2007, 28:2298-2304.
22. Huen M.S., Chen J. The DNA damage response pathways: at the crossroad of protein modifications. Cell Res. 2008, 18:8-16.
23. Rappold I., Iwabuchi K., Date T., Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J. Cell Biol. 2001, 153:613-620.
24. Tauchi H., Matsuura S., Kobayashi J., Sakamoto S., Komatsu K. Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene 2002, 21:8967-8980.
25. Tan J., Sharief Y., Hamil K.G., Gregory C.W., Zang D.Y., Sar M., Gumerlock P.H., deVere White R.W., Pretlow T.G., Harris S.E., Wilson E.M., Mohler J.L., French F.S. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 1997, 11:450-459.
26. Takahashi S., Watanabe T., Okada M., Inoue K., Ueda T., Takada I., Watabe T., Yamamoto Y., Fukuda T., Nakamura T., Akimoto C., Fujimura T., Hoshino M., Imai Y., Metzger D., Miyazono K., Minami Y., Chambon P., Kitamura T., Matsumoto T., Kato S. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. Proc Natl Acad Sci U S A 2011, 108:4938-4943.